

## Daftar Pustaka

1. Inker L, Astor B, Fox C. KDIGO 2012 Clinical practice guideline for the evaluation and management of CKD. *Kidney inter, suppl.* 2013; 3:1–150.
2. Fauziati A. Global challenge of early detection and management of chronic kidney disease. *Indonesian Journal of Medicine and Health.* 2017; 8:1–3.
3. Chronic Kidney Disease surveillance system website. <http://www.cdc.gov/ckd>. Accessed March 9, 2017.
4. Hill N, Fatoba S, Oke J, O'Chollagan C, Lasserson D, Hobbs R, et al. Global Prevalance of Chronic Kidney Disease- a systemic review and meta analisis. *Plos one Journal.* 2017 July; 11(7): 1–18.
5. PERNEFRI. 5th Report of Indonesian Renal Registry. 2012.
6. Kemenkes. Riset Kesehatan Dasar (RISKESDAS). Jakarta. ; 2013.
7. Levey A, Coresh J. Chronic kidney disease. *Lancet.* 2012 January; 379(9811):165–80.
8. Kraut J, Madias N. Metabolic acidosis of CKD: Pathophysiology, diagnosis and management. *Nat Rev Nephrol.* 2010; 6(5): 978–93.
9. Chen W, Abramowitz M. Metabolic acodosis and the progression of chronic kidney Disease. *BMC Nephrology.* 2014; 15(55):1–8.
10. Moranne O, Froissart M, Rosset J, Gauci C, Boffa J. The Nephrotest Study Group: Timing of onset of CKD-related metabolic complications. *J Am Soc Nephrol.* 2009; 20(1):164–71.
11. Ortega L, Arora S. Metabolic acidosis and progression of Chronic Kidney Disease , Pathogenesis and Therapeutic therapy. *Revista Nephrologia.* 2012; 32(6): 724.
12. Shah S, Abromowitz M, Hostetter T, Melamaed M. Serum bicarbonat leves and the progression of Kidney disease : cohort study. *Am J Kidney Dis.* 2009; 54(2):270–77.
13. Kovesdy C, Anderson J, Kalandar ZK. Association of serum bicarbonat levels with mortality in patients with non dialysis depend CKD. *Nephron Dial Transplant.* 2009; 24(4):1232–37.
14. de Brito A, Varaganam M, Raftery M, yaqoob M. bicarbonat supplementation slows progression of CKD and improve nutrituional status. *J Am Soc.Neph.* 2009; 20:2075–84.

15. Dubey A, Sahoo J, Vairappan B, Haridasan S, Parameswaran S, Priyamvada P. Correction of metabolic acidosis improve muscle mass and renal fuction in CKD stage 3 and 4: A Randomized control trial. *Nephrol Dial Transplant*. 2018; 1–9.
16. Kraut J, Madias N. Metabolic Acidosis of CKD: An update. *Am J Kidney Disease*. 2016; 67(2):301–17.
17. Goraya N, Wesson D. Does correction of metabolic acidosis slow CKD progression ? *Curr opin Nephrol hypertension*. 2013; 22(2):193–7.
18. Kraut J. Effect of metabolic acidosis on progression of Chronic Kidney Disease. *Am J Physiol Renal Physiol*. 2011; 300(4):F828–29.
19. Kohan E, Inscho E, Wesson D , Pollock D. Physiology of endhotelin and the kidney. *Compr Physiol*. 2011 april; 1(2):883–919.
20. Kitamura K, Tanaka T, Kato J. Regional distribution of immunoreactive endothelin in porcine tissue: abundance of inner medula of the kidney. *Biochem Biophys res Commun*. 1989; 161:348–52.
21. Barton M, Sorokin A. Endothelin and glomerulus in ChronicKidney Disease. *Semin Nephrol*. 2015 Maret; 35(2):156–67.
22. Kohan D. Introduction: bisic biology of renal Endothelin system. *Sem. Nephrol*. 2015 March; 35(2):121–24.
23. Dhaun N, Webb D, Kluth D. Endothelin-1 and the Kidney - beyond BP. *British J of Pharmacol*. 2012; 167:720–31.
24. Zager R, Johnson A, Andress D. Progressive endothelin-1 gene activation initiates chronic/ end-stage renal disease following experimental ischemic/reperfusion injury. *Kidney int*. 2013; 84:703–12.
25. Barton M, Sorokin A. Endothelin and glomerulus in ChronicKidney Disease. *Semin Nephrol*. 2015 Maret; 35(2):156–67.
26. Wesson D, Simoni J, Green D. Reduced extraselluler PH increased endothelin-1 Secretion by Human Renal Microvascular Endhotelial Cells. *J. Clin. Invest*. 1998 February; 101(3):578–83.
27. Wesson D, Simoni J. Acid retention during kidney failure induces endothelin and aldosteron production which lead to progressive GFR decline, A situation ameliorate by alkali diet. *Kidney international*. 2010; 78:1128–35.
28. Mathieson P. The podocyt as a target for theraphies new and old. *Nat rev Nephrol*. 2012;

8:52–6.

29. Pallini A, Hulter H, Muser J. Role of endothelin-1 in renal regulation of acid base equilibrium in acidotic humans. *Am J Renal Physiology*. 2012; 303:F991–9.
30. Suwita K. Penyakit Ginjal kronik. In Setiati S, Alwi I, Sudoyo A, editors. *Buku ajar Ilmu penyakit dalam*. Jakarta: Interna Publishing; 2014. p. 2159–65.
31. Thomas R, Kanso A, Sedor J. Chronic kidney disease and complications. *Prime Care*. 2008; 35(2):329–37.
32. Rao S, Nagendranath V. Arterial Blood gas monitoring. *Indian Journal of anesthesia*. 2008; 46(4):289–97.
33. Kovesdy C. Pathogenesis, consequences, and treatment of acidosis metabolic in chronic kidney disease. *UpToDate*. 2016 july; 1–11.
34. Moenadajat Y, Madjid A, Siregar P, Wibisono L, Loho T. *Gangguan keseimbangan air-elektrolit dan asam basa Jakarta: UPK-PKB FKUI; 2012.*
35. Adamvzak M, Zagajewska A, Mazanowska O, Madziarska K, Stompor T, Wiecek A. Diagnosis and treatment of metabolic acidosis in patient with CKD-position statement of working group of the polish society nephrology. *Kidney and blood pressure research*. 2018 June; 43:959–69.
36. Clase C, Kibert B, Garg A. Relationship between GFR and prevalence of metabolic abnormalities: Result from NHNES III. *Nephron Clin Pract*. 2007; 105:178–84.
37. Dobre M, yang W, pan Q. Persistent high serum bicarbonat and the risk of heart failure in patients with chronic kidney disease (CKD): report from the CRIC study. *Am J Heart association*. 2015; 4(4):1–10.
38. Schambelan M, Sebastian A, Katuna B, Arteaga E. Adrenocortikal hormone respon to chronic NH<sub>4</sub>Cl induced metabolic acidosis. *Am J Physiol*. 2011; 252:454–60.
39. Loniewski I, Wesson D. Bicarbonat therapy for prevention CKD progression. *Kidney International J*. 2014; 85:529-35: p. 98–106.
40. Miguel C, Speed J, Kasztan M, Gohar E, David M. Endothelin-1 and the Kidney : new perspective and recent finding. *Curr Opin Nephrol Hypertens*. 2016; 25(1):35–41.
41. Babulescu A, Moe , Moe OW. Na/H Exchangers in renal regulation of Acid Base Balance. *Semin Nephrol*. 2010; 26(5):334–44.
42. Barton M, yanagisawa M. Endothelin : 20 years from discovery to therapy. *Can J Physiol*

Pharmacol. 2008; 86:485–98.

43. Kuc R, Davenport A. Comparison of Endothelin-A and endothelin-B receptor distribution visualized by radioligand binding versus immunocytochemical localization using subtype selective antisera. *J Cardiovasc Pharmacol*. 2004; 44:224–6.
44. Dhaun N, Goddard J, Webb D. The endothelin system and its antagonism in chronic kidney disease. *J Am Soc Nephrol*. 2006; 17:943–55.
45. Guo J, Cantley L. Cellular maintenance and repair of the kidney. *Ann Rev Physiol*. 2010; 72:357–76.
46. Kohan D, Barton M. Endothelin and endothelin antagonist in CKD. *Kidney Int*. 2014 November; 86(5):896–904.
47. Vuurmans J, Boer P, Koomans H. Effects of Endothelin-1 and Endothelin-1 receptor blockade on renal function in human. *Nephrol Dial Transplant*. 2004; 19:2742–46.
48. Kohan D, Barton M. Endothelin and Endothelin Antagonist in Chronic Kidney disease. *Kidney Int*. 2014 November; 86(5):896–904.
49. Hofer B, Thone-Reineke C, Rohmeiss P. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cyst but not hypertension. *J Clin Invest*. 1997; 99:1380–89.
50. Morigi M, Buelli S, Zanchi S. Shigatoxin induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodelling. *Am J Pathol*. 2006; 169:1965–75.
51. Rebibou J, He C, Delarue F, Delarue F. Functional endothelin 1 receptors on human and glomerular podocytes and mesangial cells. *Nephrol Dial Transplant*. 1992; 7:288–92.
52. Morigi M, Buelli S, Angioletti S. In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. *Am J Pathol*. 2005; 166:1309–20.
53. Minchenko A, Stevens M, White L. Diabetes induced overexpression of ET-1 and ET receptors in rat renal cortex is mediated via poly (ADPribose) polymerase activation. *FASEB J*. 1998; 17:1514–16.
54. Rabelink T, Kaasjager K, Stoes E, Koomans H. Endothelin in renal pathophysiology: From experimental to therapeutic application. *Kidney Int*. 1996 March; 50:1827–33.
55. Ortman J, Amann K, Brandes R, et al. Role of podocytes for reversal of glomerulosclerosis and proteinuria in aging kidney after endothelin inhibition. *Hypertension*. 2004; 44:947–81.

56. Schneider J, Tilly N, Hierl T, Sommer U, Hamann A, Dugi , et al. Elevated plasma endothelin-1 levels in Diabetes mellitus. *Am J*. 2002 Nov; 15(11):967–72.
57. Alam I, Bass N, Bacchetti P, Gee L, Rockey D. Hepatic tissue endothelin-1 level in chronic liver disease correlate with disease severity and ascites. *Am J Gastroenterol*. 2000 jan; 95(1): 199–203.
58. Trakada G, Spiropoulos K, Nikolaou E, Prodromakis E, Efremidis G, Pouli A, et al. Endothelin-1 levels in the pathophysiology of chornic pulmonary disease and bronchial astma. *Respir Med*. 2011; 97(8): 983–89.
59. Parker D, Thiessen J. Incrteased endothelin-1 in patients with chronic heart failure. *Am J PhysiolHeart Circ Physiol*. 2004; 286(3):1141–15.
60. Soelistijo S. *Konsensus pengelolaan dan pencegahan diabetes mellitus di Indonesia* Jakarta: PB PERKENI; 2015.
61. Rajapurkar M, John G, Kirpalani A. What do we know about chronic kidney disease in india: first report of the Indiaan CKD registry. *BMC nephrol*. 2012; 13:10.
62. Rosalinda R. Perbedaan kadar IL-6 serum dengan jumalh CD34 EPC serum berdasarkan nilai ABI pada pasien PGK. 2019 (unpublish).
63. Nitta K, Okada K, Yanai M, Takahashi S. Aging and Chronic Kidney Disease. *Kidney and blood pressure research*. 2014; 38:109–20.
64. Wen C, Yueh T, Lung C, Hwee Y, Wei H, Pei T, et al. the number of comorbidities Predict renal outcomes in patient with Stage 3-5 CKD. *J Clinical med*. 2018; 7(493):1–8.
65. Goldberg I, Krause I. The role of gender in Chronic kidney disease. *European medical Journal*. 2016; 1(2):58–64.
66. Frassetto L, Hsu C. Metabolic acidosis and progression of Chronic kidney disease. *J Am Soc Nephron*. 2009; 20:1869–70.
67. Kopple J, Zadeh K, Mehrotta R. Risk of Metabolic acidocis in patient with chronic kidney disease. *Kidney int*. 2005; 67(95):21–7.
68. Eustace J, Astor B, Muntner P, Ikizler T, Coresh J. Prevalence of acidosis and inflamation and their association with low serum albumin in chronic kidney disease. *Kidney int*. 2004; 65:1031–40.
69. Inker L, Astor B, Fox C, et al. KDOQI US Commentary on the 2012 KDIGO Clinical practice Guideline fer the evaluation and menagement. *AM J Kidney Dis*. 2014.

70. Yacoob M. Acidosis and progression of Chronic kidney disease. *Curr Opin Nephrol hypertens.* 2010; 19: 489–92.
71. Benigni A, Perico N, Gaspari F, Zoja C, Bellizzi M, Gabanelli M, et al. Increased renal endothelin production in rats with reduced renal mass. *Am J Physiol.* 1991; 260:F331–39.
72. Fieldman D, Mogelesky T, Chow M, Jeng A. Enhance expression of endothelin-converting enzyme and endothelin A-receptor mRNA in rats with interstitial fibrosis following ureter ligation. *J Cardiovasc pharmacol.* 2000; 36(suppl 1): S255–59.
73. Remuzzi G, Benigni A. Endothelins in the control of cardiovascular and renal funtion. *lancet.* 1993; 342:589–93.
74. Chen W, Abramowitz M. Metabolic acodosis and the progression of chronic jidney Disease. *BMC Nepgrology.* 2014; 15(55):1–8.
75. Barton M, Tharoux P. Endothelin and the podocyte. *Clin Kidney J.* 2012; 5:17–27.
76. Navaneethan s, Shao J, Buysee J, Bushinsky D. Effects of treatment acidosis metabolic in CKD. Asystemic review and meta Analysis. *CJSSN.* 2019 July; 14:1–10.

